




>Glyma.06G072000

FwPr 

CACATATCACCGAAAAATAAATTAAATTAAAAAATTAGATGATCAAATTAATAAATAAATAAATAAATTGATGAAATTAAATCG  
 ATTTTAAAAAATAAAAAATAAATGAAAGTTACGGAATTGAAATATCTAAATCCAGAAGAAGAGTGAAGGGGAAACTTGTTTA  
 ATCGGTTAGTTTCCCTATTACGAAATTGTTTGACATAATTTTTCAATGAATCCTCTTGTTTGAAACTTACATAAGTTTGATC  
 GAGGAAGTCCAAATTTTCATCCAAGATGCATGGAGAGACTGTGACAAGCGTGTCTCTACTGGGCAACGCGAGATTGCTGCAA  
 ACACGGCAAGCAATAGGTAGCACCAAAACAAGATGCTAAACTCAACCAATTAATTAAGTAATAATGGTGGCTTTGCCAT  
 TTGGAATACGCCCTCTCCACTGTGCCAAACAATAACTCCCACCTTTTCGATCTCCTAATTACTATTTACATTTCAAGCTTT  
 TCTGCTTCCTCATATCTCTCTATATATGCTTCCTTTAGTTCTAAGTCAAGACTTTTATAATTAAGGTAAGAGGGTCATCGTG  
 GAAGGATTTATAAATTTCTCAACTCAACTCTCACCATGAGGACCAATTGCTTCCTAAGCCTTCCCTTTTACTTCAAACCA  
 ACCTTCCATTCCCCAAAACATCCTCAACTTTTCATCGTAAGTTTTCATCTTTGTTTCTACATACATATATTTTCTTTAACTT  
 GTTGGGTCACAATTTACATGTCATTTATGTGACTCATGTCACCTAACATTACCGTGTGCGTTGTAATAAAGGGTGAAGAACGAA  
 GCATGTTGGAAGAGGCAATGCGTTGTGATGGGAGTGGCATCCATTATTGGACTAGAAATGTGCAATTCAGTGGCAATGGCCCA  
 CGAAGCAATTGAAATCAAGACCATGCCATTTAGTAACCAAGTAGTATCAAATAGCAATTCCTACGGTGGCGCCAAATGGAGCG  
 AGAAAAGAAATGTGCCACCTTGGCAAGGCAATTCGCTCGAAACGATCGTGCCGGAGAATCTCCCCGGCCGTCGGCACGGCGG  
 AGATACGAGGCTGTTTCGTTCCCTCCAAGACTGCGCCGCCGCTCTCCGCCCTATCATAGTCCAAAGCAACAAGGGCAGTTG  
 CTTCTCCATGTGAAAAATACTAAATCAAATTAATTTACTTGTACATGATTATTGTTAATTTAATTGCTTGGCCTTTACACA  
 AACTTTTAATTTTCAATCATATCCATGTGTCAAGTTTTATTTCTTTGGATGAAAACTTCAAAAATATCTAACGAATAATTGT  
 ATGTAATGAATAGTACTAGTACTGGATTGGATTTATGCAAGTTTATGATGATTGTAGTACATGTAGTACAAATCTAATTCGTTA  
 CCTATCTTAAACCATGCACAAGCACAAACATTGTACTACACTGCTTCCCATCTTTTCTTGTGTTTCGTTTTTGTGCTTTC  
 TGAAGCCCATAGTTTTATAGGCCTGCGGCCCTATTGCTTTCTATTGGGCTGGTTCATCAGGCCATTATCGCTAACGCACAT  
 TCCTCGTTAAATTTGTTGCTATCTGTTTCATCGTCCCGCCAATTTTATGCGATTATATTTAAATTTTAAATTTAAGAAAAA  
 GAATTTAAACATTAAATTACGTGTTATATAAATATTGATGGGACTATGAAGTCCACAGAATCACTTAATAATTTCTCCCATG  
 CAAAGATAATTCTTGAATCACATACCACCAGAGCTATTTTGTCTCCG RvPr 

**Figure S1.** Sequence information for RNP activity assays. sgRNA target sequences and primer sequences: 5'-untranslated region; exons; 3'-untranslated region. FwPr: forward primer; RvPr: Reverse primer. SgRNA-1 and sgRNA-2 target regions are boxed.





**Figure S2.** MBP removal from MBP-*SpCas9*-GFP.

Eluted MBP-*SpCas9*-GFP from IMAC was dialyzed overnight at 4°C with constant stirring against buffer A IEX using a dialysis tubing with a cutoff > 12 kDa. One 1mg TEV-P was used for every mg of protein, in the presence of 1 mM DTT and 1 mM EDTA. A sample of the protein mixture was loaded in the gel, showing partial digestion (pre-IMAC2). A second IMAC (IMAC2), performed under the same conditions as IMAC1 was done to recover *SpCas9*-GFP, which can be observed in the flow through (FT). MBP-*SpCas9*-GFP was retained in the IMAC column and eluted with imidazole (EF1: eluted fraction 1). SDS-PAGE was run in an 8 % acrylamide-bisacrylamide gel.